Navigation Links
Alzheimer's Drug Shows Promise in Fighting Cancer

LOS ANGELES, April 17, 2007 /PRNewswire/ -- Researchers from the Barbara Ann Karmanos Cancer Institute in Detroit, MI presented strong evidence today that an antibiotic typically prescribed for Alzheimer's patients could be effective in eventually treating certain types of cancers.

Q. Ping Dou, Ph.D., leader, Prevention Program at Karmanos, and members of his lab announced the findings of their study showing that the drug Clioquinol (CQ) appears to have an anti-tumor effect in mice bearing human prostate cancer cells. The announcement was made at the American Association of Cancer Research (AACR) annual meeting in Los Angeles, CA.

Dr. Dou and his team turned to the copper-binding compound CQ after discovering that prostate, breast, brain, colon and lung tumor tissue often have a higher level of copper than normal tissue. According to Dr. Dou, this led his team to investigate whether cancers with high levels of copper can lead to targeted treatment.

Karmanos researchers found that after binding CQ to the copper in prostate tumor tissue, the drug induces cell death in human prostate cancer cells.

According to Dr. Dou, his lab will take this information and work with Karmanos clinicians to create a treatment selectively targeting the copper found in tumors.

"We want to find out if we can target cancers that express high levels of copper," says Dr. Dou. "We hope to discover a compound that promotes tumor-killing activity."

The AACR was founded in 1907 by a group of eleven physicians and scientists interested in research, "to further the investigation and spread the knowledge of cancer." Today, AACR accelerates progress toward the prevention and cure of cancer by promoting research, education, communication, and advocacy.

Based in midtown Detroit, the Barbara Ann Karmanos Cancer Institute is committed to a future free of cancer. The Institute is one of 39 National Can cer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. John C. Ruckdeschel, M.D. is the Institute's president and CEO.

Barbara Ann Karmanos Cancer Institute

CONTACT: Courtney McCrimmon, +1-412-225-6899, or Linda Remington,+1-313-576-8614, both of Barbara Ann Karmanos Cancer Institute

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. At the 2007 Alzheimers Association International Conference on the Prevention of Dementia - Neurochems U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)
5. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
6. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
7. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
8. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
9. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
10. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
11. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
Post Your Comments:
(Date:11/25/2015)... 25, 2015 - Will Also ... (CME) --> - Will ... Education (CME) --> - Will ... Continuing Medical Education (CME) Elsevier , ... services, will feature latest diagnostic imaging textbooks and decision support tools, ...
(Date:11/24/2015)... 25, 2015 The hope of ... failure of IVF cycles. After failure of over 15 ... had lost all hopes that she would be able to conceive ever. But finally optimism ... conceived after failure of over 15 IVF cycles. ... they decided to take one last attempt with Gaudium IVF Center in ...
(Date:11/24/2015)... 24, 2015  Array BioPharma Inc. (Nasdaq: ... Officer, Ron Squarer , will present at ... York.  The public is welcome to participate in ... BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron ... 2015Time:1:30 p.m. Eastern Time Webcast: , ...
Breaking Medicine Technology:
(Date:11/25/2015)... IL (PRWEB) , ... November 25, 2015 , ... ... to six decades of music, friendships, and learning in its 65th Anniversary Brillianteen ... held Dec. 5-6. , For 65 years, Brillianteen has been a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Today, Mothers ... our nation’s roadways has dropped below 10,000 for the first time since 2011. In ... 2013. , According to data released by the National Highway Traffic Safety Administration (NHTSA), ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When ... that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In ... She developed the patent-pending RECOVERY BRA for added comfort and support. The bra ...
(Date:11/25/2015)... ... , ... Many people know of the common symptoms of low thyroid hormone ... But many people who find their cholesterol levels and weight are creeping up are ... if they don’t have any of the other symptoms. , Thyroid hormone plays a ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
Breaking Medicine News(10 mins):